hafnium oxide
Small moleculeexperimental
Clinical trial activity
11 trials · 9 clinical orgs · 0 marketing orgs
Phase 1
8
Phase 2
8
Phase 3
1
Phase 4
0
Earliest trial started Nov 1, 2015 (NCT02721056)
Timeline
Indications
Studied for
- Aged · Phase 3
- Breast Neoplasms · Phase 1/Phase 2
- Carcinoma, Non-Small-Cell Lung · Phase 1/Phase 2
- Carcinoma, Renal Cell · Phase 1/Phase 2
- Esophageal Neoplasms · Phase 1
- Immunotherapy · Phase 1/Phase 2
- Liver Neoplasms · Phase 1/Phase 2
- Lung Neoplasms · Phase 1/Phase 2
- Melanoma · Phase 1/Phase 2
- Neoplasm Metastasis · Phase 1/Phase 2
- Neoplasms · Phase 1/Phase 2
- Pancreatic Neoplasms · Phase 1
- Prostatic Neoplasms · Phase 1/Phase 2
- Radiotherapy · Phase 1/Phase 2
- Squamous Cell Carcinoma of Head and Neck · Phase 3
- Uterine Cervical Neoplasms · Phase 1
Mechanism of action
- Unspecified targetUnclear
unclear
Chemistry & pharmacology
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4298051 ↗
Also known as
- nbtxr3
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07224152 | Phase 1/Phase 2 (Phase 2) | Apr 30, 2026 | Nanobiotix, University of Texas at Houston |
| NCT05039632 | Phase 1/Phase 2 (Phase 2) | Nov 30, 2021 | National Cancer Institute (NCI), University of Texas at Houston |
| NCT04892173 | Phase 3 | Jul 31, 2021 | Curie Institute, Nanobiotix, University of San Francisco |
| NCT04862455 | Phase 2 | Apr 7, 2021 | University of Texas at Houston |
| NCT04834349 | Phase 2 | Mar 9, 2021 | University of Texas at Houston |
| NCT04505267 | Phase 1 | Feb 10, 2021 | National Cancer Institute (NCI), University of Texas at Houston |
| NCT04615013 | Phase 1 | Oct 31, 2020 | National Cancer Institute (NCI), University of Texas at Houston |
| NCT04484909 | Phase 1 | Jul 1, 2020 | National Cancer Institute (NCI), University of Texas at Houston |
| NCT03589339 | Phase 1/Phase 2 (Phase 2) | Sep 21, 2018 | Nanobiotix |
| NCT02805894 | Phase 1/Phase 2 (Phase 2) | Nov 1, 2016 | Harvard University, Nanobiotix, Thomas Jefferson University, University of California, Los Angeles |
| NCT02721056 | Phase 1/Phase 2 (Phase 2) | Nov 1, 2015 | IQVIA, Nanobiotix |
Showing 11 of 11 trials
Page 1 / 1
Organizations
Research & Development (9)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| University of Texas at Houston | Academic/Hospital | 7 | 7 | 2 | 2020 |
| Nanobiotix | For profit | 5 | 4 | 2 | 2015 |
| National Cancer Institute (NCI) | Government | 4 | 0 | 2 | 2020 |
| Curie Institute | Academic/Hospital | 1 | 0 | 1 | 2021 |
| Harvard University | Academic/Hospital | 1 | 0 | 1 | 2016 |
| IQVIA | For profit | 1 | 0 | 1 | 2015 |
| Thomas Jefferson University | Academic/Hospital | 1 | 0 | 1 | 2016 |
| University of California, Los Angeles | Academic/Hospital | 1 | 0 | 1 | 2016 |
| University of San Francisco | Academic/Hospital | 1 | 0 | 1 | 2021 |
9 organizations
Page 1 / 1